A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer

被引：0
|
作者：
Cody J. Peer
Keith T. Schmidt
Jessica D. Kindrick
Joel R. Eisner
Victoria V. Brown
Edwina Baskin-Bey
Ravi Madan
William D. Figg
机构：
[1] National Cancer Institute,Clinical Pharmacology Program, CCR
[2] NIH,Genitourinary Malignancies Branch
[3] Innocrin Pharmaceuticals,undefined
[4] National Cancer Institute,undefined
[5] NIH,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Seviteronel CYP17 lyase; Population pharmacokinetics; Prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：759 / 770
页数：11
相关论文
共 50 条
  • [31] Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
    Reid, Alison H. M.
    Attard, Gerhardt
    Danila, Daniel C.
    Oommen, Nikhil Babu
    Olmos, David
    Fong, Peter C.
    Molife, L. Rhoda
    Hunt, Joanne
    Messiou, Christina
    Parker, Christopher
    Dearnaley, David
    Swennenhuis, Joost F.
    Terstappen, Leon W. M. M.
    Lee, Gloria
    Kheoh, Thian
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric
    Scher, Howard I.
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1489 - 1495
  • [32] Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer
    Sharp, Adam
    Welti, Jonathan
    Blagg, Julian
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2016, 22 (17) : 4280 - 4282
  • [33] The androgen receptor transcriptional program in castration-resistant prostate cancer
    Roth, Jeffrey E.
    Peer, Cody J.
    Price, Douglas K.
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2014, 15 (01) : 16 - 18
  • [34] Persistent androgen receptor addiction in castration-resistant prostate cancer
    Michael T. Schweizer
    Evan Y. Yu
    Journal of Hematology & Oncology, 8
  • [35] A new androgen receptor antagonist Darolutamide for patients with non-metastatic castration-resistant prostate cancer
    Kesch, C.
    Hadaschik, B. A.
    UROLOGE, 2019, 58 (10): : 1217 - 1218
  • [36] Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
    Sharifi, Nima
    ENDOCRINOLOGY, 2013, 154 (11) : 4010 - 4017
  • [37] Persistent androgen receptor addiction in castration-resistant prostate cancer
    Schweizer, Michael T.
    Yu, Evan Y.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [38] Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor
    Elias, Anthony
    Gucalp, Ayca
    Bardia, Aditya
    Resaul, Andrew
    Eisner, Joel
    Baskin-Bey, Edwina
    Traina, Tiffany A.
    CANCER RESEARCH, 2018, 78 (04)
  • [39] Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
    Singh, Krishna B.
    Ji, Xinhua
    Singh, Shivendra V.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (10) : 2079 - 2090
  • [40] Survival outcomes among metastatic castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitor and docetaxel.
    Hwang, Yunji
    Wheeling, Travis
    Hatfield, Mark
    Kim, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
12345